Investor Presentation on Q4FY26 Financial Results
GLAND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Gland Pharma reported strong Q4FY26 results with consolidated revenue of ₹17,428 million (up 22% YoY) and FY26 revenue of ₹64,307 million (up 14% YoY). The base business (Gland) grew 22% YoY to ₹12,648 million in Q4 with operating margins expanding significantly - Adj. EBITDA margin improved to 41% from 38% YoY. Adjusted PAT for Q4FY26 surged 97% YoY to ₹3,667 million, driven by new product launches (31 products in US during FY26 including Dalbavancin, Liraglutide), cost reduction initiatives, and operating leverage. The company filed 24 ANDAs and received 28 approvals in FY26 with 388 cumulative ANDA filings. European subsidiary Cenexi showed revenue of €45 million in Q4 with ongoing ramp-up at facilities. The Board recommended a final dividend of ₹20 per share.
Strong margin expansion and near-doubling of PAT indicate improved operational efficiency and product mix benefits. The robust US pipeline (337 approved ANDAs) and new CDMO contract support long-term growth. Net cash position of ₹31,157 million provides significant financial flexibility.